Takahashi H, Nakada T, Puisieux I
Molecular Hepatology Laboratory, Massachusetts General Hospital Cancer Center, Charlestown 02129.
Science. 1993 Mar 5;259(5100):1460-3. doi: 10.1126/science.8451642.
Advanced human colon cancer does not respond to lymphokine-activated killer (LAK) cells. In order to direct cytotoxic cells to the tumor, human LAK cells linked with antibodies to a tumor cell surface antigen were tested with established hepatic metastases in severe combined immunodeficient (SCID) mice. These cells had increased uptake into the tumor and suppression of tumor growth as compared with LAK cells alone, thereby improving the survival of tumor-bearing mice. Thus, tumor growth can be inhibited by targeted LAK cells, and SCID mice can be used to test the antitumor properties of human effector cells.
晚期人类结肠癌对淋巴因子激活的杀伤细胞（LAK细胞）无反应。为了将细胞毒性细胞导向肿瘤，将与肿瘤细胞表面抗原抗体相连的人类LAK细胞在严重联合免疫缺陷（SCID）小鼠的已建立肝转移模型中进行了测试。与单独的LAK细胞相比，这些细胞对肿瘤的摄取增加且肿瘤生长受到抑制，从而提高了荷瘤小鼠的存活率。因此，靶向LAK细胞可抑制肿瘤生长，且SCID小鼠可用于测试人类效应细胞的抗肿瘤特性。
